Free tool
FAERS Monitor: Skyrizi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761105 or its brand name (Skyrizi, Risankizumab-Rzaa). Reports on generic versions are filed under their own applications.
Reports
86,264
Serious
57,158
66% of reports
Hospitalization
19,467
Death reported
3,115
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- psoriasis8,117
- drug ineffective3,773
- pain3,387
- fatigue3,279
- arthralgia3,261
- device issue2,933
- pruritus2,798
- death2,379
- surgery2,376
- fall2,347
- covid-192,283
- crohn^s disease2,240
- diarrhoea2,169
- headache1,994
- rash1,569
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 357 |
| 2020 | 1,931 |
| 2021 | 4,103 |
| 2022 | 16,392 |
| 2023 | 15,176 |
| 2024 | 14,507 |
| 2025 | 19,572 |
| 2026 | 14,223 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,967,895 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| psoriasisSignal | 8,117 | 16.1 | 15.7 | 108,399 |
| surgerySignal | 2,376 | 10.3 | 9.8 | 19,088 |
| device issueSignal | 2,933 | 8.2 | 7.9 | 18,033 |
| covid-19Signal | 2,283 | 3.2 | 3.1 | 3,437 |
| arthralgia | 3,261 | 1.9 | 1.9 | 1,453 |
| pruritus | 2,798 | 1.8 | 1.7 | 968 |
| fall | 2,347 | 1.7 | 1.7 | 720 |
| pain | 3,387 | 1.3 | 1.3 | 309 |
| fatigue | 3,279 | 1.0 | 1.0 | 2 |
| rash | 1,569 | 0.9 | 0.8 | 27 |
| diarrhoea | 2,169 | 0.8 | 0.8 | 89 |
| headache | 1,994 | 0.8 | 0.7 | 134 |
| drug ineffective | 3,773 | 0.7 | 0.7 | 528 |
| death | 2,379 | 0.7 | 0.6 | 395 |
| crohn^s disease | 2,240 | 0.0 | 0.0 | 544,283 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.